Popular Articles
Benefits Of Grapefruit

Stellar Pharmaceuticals Inc. Announces Watson Pharma, Inc. Has Received A Conditional IDE Approval For Stellar's Uracyst(R) From The FDA
Stellar Pharmaceuticals Inc. ("Stellar" or the "Company") (OTCBB:SLXCF) is pleased to announce that its United States licensee, Watson Pharma, Inc. ("Watson") (NYSE:WPI), has received a conditional approval of their Investigational Device Exemption (IDE) to conduct clinical work with Uracyst® from The Food and Drug Administration (FDA) in the United States of America ("USA"). This will allow Watson to continue to move their Uracyst® development program forward towards the eventual approval for the sale of Uracyst® in USA. The conditional approval allows Watson to begin a blinded, placebo-controlled, pilot clinical trial in 100 subjects at 20 clinical study centers in the USA.
generic viagra online
Philippines Health Secretary Warns Of Impending Dengue Threat
With the start of the rainy season, Francisco Duque III, health secretary in the Philippines, on Tuesday emphasized a continued government commitment to controlling and preventing dengue - a disease for which there is currently no vaccine or specific drug, the Manila Times reports.
News of the day
Depuy Mitek Launches Small Joint Anchors Now Pre-Loaded With Orthocord(R) - Small, Strong And Secure Solutions For Soft Tissue Fixation
DePuy Mitek, Inc., a leading orthopaedics sports medicine company, announced that all of its QUICKANCHOR® Plus suture anchors for small joint repair are now available pre-loaded with ORTHOCORD®. ORTHOCORD is the only high-strength, partially absorbable orthopedic suture on the market designed to provide a supple solution for soft tissue fixation while maintaining strength and knot security. The QUICKANCHOR Plus small joint suture anchors with ORTHOCORD include the MINI, MINILOK™, MICRO and MICROFIX™ product families.
Health Insurance

Flu Shot Not Effective In Preventing Flu-Related Hospitalizations In Asthmatic Children

The inactivated flu vaccine does not appear to be effective in preventing influenza-related hospitalizations in children, especially the ones with asthma. In fact, children who get the flu vaccine are more at risk for hospitalization than their peers who do not get the vaccine, according to new research that will be presented on Tuesday, May 19, at the 105th International Conference of the American Thoracic Society in San Diego. Flu vaccine (trivalent inactivated flu vaccine TIV) has unknown effects on asthmatics. "The concerns that vaccination maybe associated with asthma exacerbations have been disproved with multiple studies in the past, but the vaccine"s effectiveness has not been well-established," said Avni Joshi, M.D., of the Mayo Clinic in Rochester, MN. "This study was aimed at evaluating the effectiveness of the TIV in children overall, as well as the children with asthma, to prevent influenza-related hospitalization." The CDC"s Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP) recommend annual influenza vaccination for all children aged six months to 18 years. The National Asthma Education and Prevention Program (3rd revision) also recommends annual flu vaccination of asthmatic children older than six months. In order to determine whether the vaccine was effective in reducing the number of hospitalizations that all children, and especially the ones with asthma, faced over eight consecutive flu seasons, the researchers conducted a cohort study of 263 children who were evaluated at the Mayo Clinic in Minnesota from six months to 18 years of age, each of whom had had laboratory-confirmed influenza between 1996 to 2006. The investigators determined who had and had not received the flu vaccine, their asthma status and who did and did not require hospitalization. Records were reviewed for each subject with influenza-related illness for flu vaccination preceding the illness and hospitalization during that illness. They found that children who had received the flu vaccine had three times the risk of hospitalization, as compared to children who had not received the vaccine. In asthmatic children, there was a significantly higher risk of hospitalization in subjects who received the TIV, as compared to those who did not (p= 0.006). But no other measured factors such as insurance plans or severity of asthm appeared to affect risk of hospitalization. "While these findings do raise questions about the efficacy of the vaccine, they do not in fact implicate it as a cause of hospitalizations," said Dr. Joshi. "More studies are needed to assess not only the immunogenicity, but also the efficacy of different influenza vaccines in asthmatic subjects." American Thoracic Society (ATS)


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):